在观察性研究中使用质量管理系统和基于风险的方法,以获得可靠的现实世界证据。

IF 2 4区 医学 Q4 MEDICAL INFORMATICS Therapeutic innovation & regulatory science Pub Date : 2024-09-03 DOI:10.1007/s43441-024-00695-6
Reo Tanoshima, Naoko Inagaki, Manabu Nitta, Soichiro Sue, Sayuri Shimizu, Tatsuya Haze, Kotaro Senuki, Chihiro Sano, Hajime Takase, Makoto Kaneko, Akito Nozaki, Kozo Okada, Kohei Ohyama, Atsushi Kawaguchi, Yusuke Kobayashi, Hideki Oi, Shin Maeda, Yuichiro Yano, Yuji Kumagai, Etsuko Miyagi
{"title":"在观察性研究中使用质量管理系统和基于风险的方法,以获得可靠的现实世界证据。","authors":"Reo Tanoshima, Naoko Inagaki, Manabu Nitta, Soichiro Sue, Sayuri Shimizu, Tatsuya Haze, Kotaro Senuki, Chihiro Sano, Hajime Takase, Makoto Kaneko, Akito Nozaki, Kozo Okada, Kohei Ohyama, Atsushi Kawaguchi, Yusuke Kobayashi, Hideki Oi, Shin Maeda, Yuichiro Yano, Yuji Kumagai, Etsuko Miyagi","doi":"10.1007/s43441-024-00695-6","DOIUrl":null,"url":null,"abstract":"<p><p>The results of observational studies using real-world data, known as real-world evidence, have gradually started to be used in drug development and decision-making by policymakers. A good quality management system-a comprehensive system of process, data, and documentation to ensure quality-is important in obtaining real-world evidence. A risk-based approach is a common quality management system used in interventional studies. We used a quality management system and risk-based approach in an observational study on a designated intractable disease. Our multidisciplinary team assessed the risks of the real-world data study comprehensively and systematically. When using real-world data and evidence to support regulatory decisions, both the quality of the database and the validity of the outcome are important. We followed the seven steps of the risk-based approach for both database selection and research planning. We scored the risk of two candidate databases and chose the Japanese National Database of designated intractable diseases for this study. We also conducted a quantitative assessment of risks associated with research planning. After prioritizing the risks, we revised the research plan and outcomes to reflect the risk-based approach. We concluded that implementing a risk-based approach is feasible for an observational study using real-world data. Evaluating both database selection and research planning is important. A risk-based approach can be essential to obtain robust real-world evidence.</p>","PeriodicalId":23084,"journal":{"name":"Therapeutic innovation & regulatory science","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Using a Quality Management System and Risk-based Approach in Observational Studies to Obtain Robust Real-World Evidence.\",\"authors\":\"Reo Tanoshima, Naoko Inagaki, Manabu Nitta, Soichiro Sue, Sayuri Shimizu, Tatsuya Haze, Kotaro Senuki, Chihiro Sano, Hajime Takase, Makoto Kaneko, Akito Nozaki, Kozo Okada, Kohei Ohyama, Atsushi Kawaguchi, Yusuke Kobayashi, Hideki Oi, Shin Maeda, Yuichiro Yano, Yuji Kumagai, Etsuko Miyagi\",\"doi\":\"10.1007/s43441-024-00695-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The results of observational studies using real-world data, known as real-world evidence, have gradually started to be used in drug development and decision-making by policymakers. A good quality management system-a comprehensive system of process, data, and documentation to ensure quality-is important in obtaining real-world evidence. A risk-based approach is a common quality management system used in interventional studies. We used a quality management system and risk-based approach in an observational study on a designated intractable disease. Our multidisciplinary team assessed the risks of the real-world data study comprehensively and systematically. When using real-world data and evidence to support regulatory decisions, both the quality of the database and the validity of the outcome are important. We followed the seven steps of the risk-based approach for both database selection and research planning. We scored the risk of two candidate databases and chose the Japanese National Database of designated intractable diseases for this study. We also conducted a quantitative assessment of risks associated with research planning. After prioritizing the risks, we revised the research plan and outcomes to reflect the risk-based approach. We concluded that implementing a risk-based approach is feasible for an observational study using real-world data. Evaluating both database selection and research planning is important. A risk-based approach can be essential to obtain robust real-world evidence.</p>\",\"PeriodicalId\":23084,\"journal\":{\"name\":\"Therapeutic innovation & regulatory science\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic innovation & regulatory science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s43441-024-00695-6\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICAL INFORMATICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic innovation & regulatory science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s43441-024-00695-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL INFORMATICS","Score":null,"Total":0}
引用次数: 0

摘要

使用真实世界数据进行观察研究的结果被称为真实世界证据,已逐渐开始用于药物开发和决策者的决策。一个良好的质量管理系统--确保质量的流程、数据和文件的综合系统--对于获得真实世界证据非常重要。基于风险的方法是介入研究中常用的质量管理系统。我们在一项针对指定难治性疾病的观察性研究中使用了质量管理系统和基于风险的方法。我们的多学科团队全面系统地评估了真实世界数据研究的风险。在使用真实世界数据和证据支持监管决策时,数据库的质量和结果的有效性都很重要。我们按照基于风险的方法的七个步骤进行数据库选择和研究规划。我们对两个候选数据库进行了风险评分,并选择日本国家指定难治性疾病数据库作为本研究的数据库。我们还对与研究规划相关的风险进行了量化评估。在对风险进行优先排序后,我们修订了研究计划和成果,以反映基于风险的方法。我们的结论是,对于使用真实世界数据的观察性研究来说,实施基于风险的方法是可行的。对数据库选择和研究计划进行评估非常重要。基于风险的方法对于获得可靠的真实世界证据至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Using a Quality Management System and Risk-based Approach in Observational Studies to Obtain Robust Real-World Evidence.

The results of observational studies using real-world data, known as real-world evidence, have gradually started to be used in drug development and decision-making by policymakers. A good quality management system-a comprehensive system of process, data, and documentation to ensure quality-is important in obtaining real-world evidence. A risk-based approach is a common quality management system used in interventional studies. We used a quality management system and risk-based approach in an observational study on a designated intractable disease. Our multidisciplinary team assessed the risks of the real-world data study comprehensively and systematically. When using real-world data and evidence to support regulatory decisions, both the quality of the database and the validity of the outcome are important. We followed the seven steps of the risk-based approach for both database selection and research planning. We scored the risk of two candidate databases and chose the Japanese National Database of designated intractable diseases for this study. We also conducted a quantitative assessment of risks associated with research planning. After prioritizing the risks, we revised the research plan and outcomes to reflect the risk-based approach. We concluded that implementing a risk-based approach is feasible for an observational study using real-world data. Evaluating both database selection and research planning is important. A risk-based approach can be essential to obtain robust real-world evidence.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Therapeutic innovation & regulatory science
Therapeutic innovation & regulatory science MEDICAL INFORMATICS-PHARMACOLOGY & PHARMACY
CiteScore
3.40
自引率
13.30%
发文量
127
期刊介绍: Therapeutic Innovation & Regulatory Science (TIRS) is the official scientific journal of DIA that strives to advance medical product discovery, development, regulation, and use through the publication of peer-reviewed original and review articles, commentaries, and letters to the editor across the spectrum of converting biomedical science into practical solutions to advance human health. The focus areas of the journal are as follows: Biostatistics Clinical Trials Product Development and Innovation Global Perspectives Policy Regulatory Science Product Safety Special Populations
期刊最新文献
Comparison of Product Features and Clinical Trial Designs for the DTx Products with the Indication of Insomnia Authorized by Regulatory Authorities. A Framework for the Use and Likelihood of Regulatory Acceptance of Single-Arm Trials Correction: Advanced Regenerative Medicines for Rare Diseases: A Review of Industry Sponsors Investment Motivations. Latest Developments in “Adaptive Enrichment” Clinical Trial Designs in Oncology Advanced Regenerative Medicines for Rare Diseases: A Review of Industry Sponsors Investment Motivations
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1